Susquehanna International Group, LLP Immunity Bio, Inc. Call Options Transaction History

Susquehanna International Group, LLP

14 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 15, 2024	SELL	$4.82 - $9.15 $2.94 Million - $5.58 Million	-610,100 Reduced 54.59%	507,500 $3.21 Million
Q1 2024 May 07, 2024	BUY	$3.23 - $6.17 $2.13 Million - $4.07 Million	659,500 Added 143.96%	1,117,600 $6 Million
Q4 2023 Feb 14, 2024	SELL	$1.25 - $5.21 $337,875 - $1.41 Million	-270,300 Reduced 37.11%	458,100 $2.3 Million
Q3 2023 Nov 14, 2023	SELL	$1.29 - $3.1 $393,321 - $945,190	-304,900 Reduced 29.51%	728,400 $1.23 Million
Q2 2023 Aug 11, 2023	BUY	$1.53 - $6.41 $1.49 Million - $6.22 Million	970,600 Added 1548.01%	1,033,300 $2.87 Million
Q1 2023 May 16, 2023	SELL	$1.35 - $4.78 $7,290 - $25,812	-5,400 Reduced 7.93%	62,700 $114,000
Q4 2022 Feb 14, 2023	BUY	$4.35 - $6.77 $16,094 - $25,049	3,700 Added 5.75%	68,100 $345,000
Q3 2022 Nov 14, 2022	BUY	$3.65 - $6.43 $113,880 - $200,616	31,200 Added 93.98%	64,400 $320,000
Q2 2022 Aug 15, 2022	BUY	$2.68 - $6.14 $54,136 - $124,028	20,200 Added 155.38%	33,200 $124,000
Q1 2022 May 16, 2022	SELL	$5.05 - $7.53 $201,495 - $300,447	-39,900 Reduced 75.43%	13,000 $73,000
Q4 2021 Feb 14, 2022	SELL	$5.67 - $10.18 $460,404 - $826,616	-81,200 Reduced 60.55%	52,900 $322,000
Q3 2021 Nov 15, 2021	SELL	$9.17 - $14.24 $231,084 - $358,848	-25,200 Reduced 15.82%	134,100 $1.31 Million
Q2 2021 Aug 11, 2021	SELL	$13.41 - $22.4 $2.99 Million - $5 Million	-223,300 Reduced 58.36%	159,300 $2.28 Million
Q1 2021 May 17, 2021	BUY	$12.83 - $42.25 $4.91 Million - $16.2 Million	382,600 New	382,600 $9.08 Million

216

63.3M

1.43M

4.12M

Ticker IBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 400,304,000
Market Cap $1.44B
Description
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.